Elanco Animal Health Incorporated $ELAN Shares Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company grew its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 34.1% during the second quarter, Holdings Channel.com reports. The fund owned 8,355,772 shares of the company’s stock after acquiring an additional 2,126,727 shares during the period. The Manufacturers Life Insurance Company’s holdings in Elanco Animal Health were worth $205,636,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the stock. Tidal Investments LLC boosted its position in shares of Elanco Animal Health by 1.4% during the 2nd quarter. Tidal Investments LLC now owns 317,878 shares of the company’s stock worth $7,823,000 after purchasing an additional 4,349 shares during the period. Integrated Wealth Concepts LLC purchased a new stake in Elanco Animal Health in the second quarter valued at approximately $35,000. NewEdge Advisors LLC raised its position in Elanco Animal Health by 17.6% in the second quarter. NewEdge Advisors LLC now owns 11,632 shares of the company’s stock valued at $286,000 after purchasing an additional 1,739 shares during the period. Squarepoint Ops LLC acquired a new position in Elanco Animal Health during the second quarter worth $3,279,000. Finally, Arizona State Retirement System boosted its position in shares of Elanco Animal Health by 1.0% during the second quarter. Arizona State Retirement System now owns 137,794 shares of the company’s stock worth $3,391,000 after buying an additional 1,316 shares during the period. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ELAN has been the topic of several research analyst reports. TD Cowen boosted their price objective on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, June 18th. Morgan Stanley lifted their target price on Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 22nd. Piper Sandler reiterated an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Weiss Ratings raised shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. Finally, Wall Street Zen cut shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.09.

Insider Buying and Selling

In other news, Director Lawrence Kurzius bought 40,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The stock was purchased at an average price of $23.40 per share, for a total transaction of $936,000.00. Following the completion of the purchase, the director owned 188,647 shares in the company, valued at approximately $4,414,339.80. This trade represents a 26.91% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Robert M. Vanhimbergen bought 4,200 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was acquired at an average cost of $23.08 per share, for a total transaction of $96,936.00. Following the acquisition, the chief financial officer directly owned 137,516 shares of the company’s stock, valued at $3,173,869.28. The trade was a 3.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders bought 63,198 shares of company stock worth $1,473,109. Corporate insiders own 1.14% of the company’s stock.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock opened at $22.89 on Friday. Elanco Animal Health Incorporated has a one year low of $18.22 and a one year high of $27.98. The company has a market cap of $11.44 billion, a PE ratio of -55.83, a P/E/G ratio of 1.76 and a beta of 1.68. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. The business has a 50-day simple moving average of $24.57 and a 200-day simple moving average of $23.93.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.07. The firm had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The firm’s revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, equities research analysts forecast that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated (NYSE: ELAN) is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites, improve animal well-being and support productivity in livestock and aquaculture.

The company’s products include vaccines, parasiticides, antibiotics, animal health pharmaceuticals and nutritional supplements. Its companion animal portfolio serves dogs and cats, while its livestock business provides products for cattle, poultry, swine and aquaculture operations.